Beam Therapeutics BEAM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$414.64M— | -$398.58M— | -$386.4M— | ||
| $22.37M+1.6% | $22.29M+1.7% | $22.07M+1.0% | $21.98M+2.0% | $22.02M+5.9% | ||
| $86.61M-26.6% | $94.24M-21.9% | $104.01M-8.0% | $110.83M+1.4% | $118.06M+13.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$51.87M-197% | ||
| $27.4M+11,910% | -$4.51M-184% | $3.36M— | $3.24M— | -$232K— | ||
| -$107K— | -$330K— | -$217K— | —— | —— | ||
| -$134.3M-262% | -$135.42M-271% | -$26.66M+79.6% | -$34.27M+74.6% | -$37.08M+74.0% | ||
| —— | —— | $6.18M+145% | -$820K+96.4% | -$12.82M-40.2% | ||
| —— | —— | —— | —— | —— | ||
| -$13.7M-4.3% | -$13.51M-4.3% | -$13.28M-4.7% | -$13.33M-7.9% | -$13.14M-22.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$945K+76.7% | $82K+101% | -$1.73M+75.9% | ||
| -$369.73M-5.2% | -$345.1M+0.6% | -$338.18M— | -$344.82M— | -$351.38M— | ||
| $14.11M+47.4% | $14.95M+67.1% | $14.18M+48.3% | $10.75M-32.6% | $9.57M-68.3% | ||
| $1.02B+62.5% | $1.21B+149% | $848.75M+57.3% | $829.84M+26.4% | $630.37M-31.0% | ||
| —— | —— | —— | $15.67M+105% | $72.93M+147% | ||
| —— | $255.15M— | $191.36M— | $127.57M— | $63.79M— | ||
| —— | —— | —— | -$144.52M-219% | $113.38M+1,703% | ||
| —— | —— | —— | —— | —— | ||
| $6.08M+30.9% | $4.77M-14.8% | $6.33M+194% | $6.16M-83.3% | $4.64M-96.8% | ||
| —— | —— | —— | —— | —— | ||
| $101.28M-78.8% | $478.05M+6,080% | $479.61M+1,162% | $479.19M+552% | $478.22M+164% | ||
| -$239.53M— | $11.51M— | —— | —— | —— | ||
| —— | $0-100% | $0-100% | $10K-85.7% | $18K-83.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$945K+76.7% | $82K+101% | -$1.73M+75.9% | ||
| $10.27M+3.2% | $10.39M+7.4% | $10.35M+7.8% | $10.21M+8.1% | $9.96M+4.5% | ||
| $940K-88.9% | $1.64M-31.7% | $1.59M— | $4.15M— | $8.5M— | ||
| —— | $255.15M— | $191.36M— | $127.57M— | $63.79M— | ||
| —— | —— | $6.18M+145% | -$820K+96.4% | -$12.82M-40.2% | ||
| —— | —— | —— | —— | -$51.87M-197% | ||
| -$13.7M-4.3% | -$13.51M-4.3% | -$13.28M-4.7% | -$13.33M-7.9% | -$13.14M-22.5% | ||
| -$107K— | -$330K— | -$217K— | —— | —— | ||
| $27.4M+11,910% | -$4.51M-184% | $3.36M— | $3.24M— | -$232K— | ||
| $14.87M-25.8% | $15.96M-29.9% | $17.34M-31.9% | $18.73M-32.5% | $20.04M-31.8% | ||
| $806.64M+7.1% | $842.49M+23.8% | $753.71M+6.7% | $696.06M-12.4% | $753.32M-19.5% | ||
| —— | $255.15M— | $191.36M— | $127.57M— | $63.79M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $2M— | ||
| —— | —— | —— | —— | —— | ||
| -$13.7M-4.3% | -$13.51M-4.3% | -$13.28M-4.7% | -$13.33M-7.9% | -$13.14M-22.5% | ||
| —— | $7.72M— | $5.79M— | —— | —— | ||
| -$383.84M-6.3% | -$360.05M-1.1% | -$352.36M— | -$355.57M— | -$360.96M— | ||
| -$383.84M-6.3% | -$360.05M-1.1% | -$352.36M— | -$355.57M— | -$360.96M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Beam Therapeutics's cash flow data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.